PubMed Health⌕ Search

Biomedical subjects

M Eriguchi

Publications and source records attributed to M Eriguchi.

59 records · Page 4Linked to original sources
PubMed1984

Oral administration of BCG as a local immunotherapy of gastrointestinal cancer.

Antitumor effect of oral bacille Calmette Guérin (BCG) administration was investigated by both animal experimentation and clinical trials. In animal experiments, orally administered BCG inhibited metastasis of syngeneic tumor from the initial site in caecum to mesenteric lymph nodes. Measurement of chemiluminescent intensity of adherent cells obtained from mesenteric lymph nodes of treated hosts revealed elevated activities of these cells. In the clinical trials it was found that marked histiocytosis occurred in mesenteric lymph nodes of stomach and colorectal cancer patients treated by the oral BCG. The 2-year survival rate of treated patients with stage IV stomach cancer (44.4%) was significantly higher than that of the untreated patients (6.3%). The results of the present study indicate that the oral BCG administration would be an effective local adjuvant therapy following radical surgery to treat patients with gastrointestinal cancer.

Administration, Oral↗
PubMedDate not supplied

Antitumor effects of a new lipophilic platinum compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), in mice.

A new lipophilic platinum (Pt) compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)Pt(lV) (C5-OHP), was compared with cisplatin (CDDP) by intraperitoneal injection for antitumor activities against 3 different mouse models, L1210 leukemia, LMFS sarcoma with high metastatic potential and spontaneous mammary tumor. C5-OHP cured both CDDP-sensitive and -resistant L1210 leukemia frequently. CDDP did not cure the leukemia, although it prolonged the survival of diseased mice significantly. C5-OHP cured early and advanced LMFS sarcomas more frequently than CDDP. Cured mice had acquired antitumor immunity, indicating the pivotal role of the immune system in induction of the cure of tumors. It is likely tllat C5-OHP can eradicate tumor cells more effectively than CDDP by virtue of its weaker suppressive effects on the immune system. C5-OHP but not CDDP could cure mammary tumors. C5-OHP manifested a curative effect against LMFS tumors by oral route. These results indicate that C5-OHP is a promising anticancer agent worthy of clinical trial.

Animals↗
PubMedDate not supplied

Adjuvant treatment of minimal residual tumors. A comparison of chemotherapy and immunotherapy.

Adjuvant chemotherapy. The frequent 6 month complete remission induction chemotherapy is not discussed here. What is under debate at present is the prolonged maintenance or adjuvant chemotherapy, which in comparative trials with 5 year follow-up does not appear to improve survival prognosis in leukemia, myeloma, non-Hodgkin lymphoma or post-menopausal breast cancer. However, it may prolong the duration of the first remission. It is suggested that the sensitivity to chemotherapy might depend on cells being induced into the G2 or M phases by growth growth promotor(s), such as estrogens in breast carcinoma. Their presence before the menopause could explain why this neoplasia in this condition is one of the few tumoral diseases transitorily sensitive to adjuvant chemotherapy. Adjuvant immunotherapy is also under debate. Immunotherapy has been reported to give a significant improvement in remission duration and/or overall survival and/or survival after relapse in several tumors and in several trials. However, for almost every trial reporting a statistically significant effect there is one (or more) which shows no significant effect. Theoretically, immunotherapy has several advantages over chemotherapy. It may be effective in minimal residual disease if tumor cells are in the G0 phase. So-called kinetic refractoriness (see separate chapter in this volume) may not apply to immunotherapy. Finally, tumor cells appear to be more sensitive than normal cells to some cytotoxic mechanisms which form a part of the biological response to tumors.

Antineoplastic Agents↗
PubMedDate not supplied

Implications of survival curve slopes on the interpretation of adjuvant therapy results.

Two mathematical models can approximate the survival curves for malignant diseases. The models identify the segments of the survival curve. Also, the hazard function of the curve and the confidence intervals of the curve could be calculated. First, we studied the survival-after-relapse curve of malignant melanoma. The curve of chemo-immunotherapy showed three segments and that for immunotherapy had two segments. The immunotherapy showed its effect in the early period of treatment. Second, the disease-free survival curves for adjuvant therapies of breast cancer were compared. In the Oncofrance trial, a combination of adriamycine, vincristine, cyclophosphamide (C) and 5-fluoro-uracil (F) (AVCF) was superior to a combination of C, methotrexate and F (CMF) in all the periods of the therapy. In Lacour's trial, poly A-poly U was more effective than the no treatment in the middle and late period. In Bonadonna's trial, CMF was superior to no treatment in the early period. Third, the survival curves for immunotherapy versus non-immunotherapy of stomach cancer were analysed. Comparison of the confidence intervals of each curve clarified that no significant difference could be found between them.

Antineoplastic Combined Chemotherapy Protocols↗